AI Article Synopsis

  • A pilot study explored the relationship between serum YKL-40 levels and complete blood count parameters in severe (GOLD stage III) and very severe (GOLD stage IV) COPD patients during acute exacerbations.
  • The study measured various blood parameters, including leukocyte counts and hemoglobin levels, in participants aged around 66 years, but found no significant differences between the two groups overall.
  • However, patients with high YKL-40 levels showed increased neutrophil percentages and neutrophil-to-lymphocyte ratios, alongside decreased lymphocyte, eosinophil, and basophil counts, indicating potential insights for tailored treatment approaches for COPD.

Article Abstract

Little information exists on YKL-40-a key protein in tissue remodeling-and complete blood count (CBC) parameters during acute exacerbations of advanced chronic obstructive pulmonary disease (COPD). This pilot exploratory study (August 2020-January 2021) investigated the connection between serum YKL-40 levels and CBC profile in sex- and age-matched individuals with severe COPD (GOLD stage III, = 23, median age = 66 years, 65.21% males) and very severe COPD (GOLD stage IV, = 24, median age = 66.5 years, 74.81% males). The measured parameters were serum YKL-40, absolute leukocyte count (ALLC), absolute neutrophil count (ANC), neutrophil percentage, absolute lymphocyte count (ALC), lymphocyte percentage, neutrophil-to-lymphocyte ratio (NLR), absolute eosinophil count (AEC), eosinophil percentage, absolute monocyte count (AMC), monocyte percentage, absolute basophil count (ABC), basophil percentage, hemoglobin levels, and hematocrit concentrations. No significant inter-group differences were observed. However, high YKL-40 subjects ( = 23)-as stratified via median YKL-40 (3934.5 pg/mL)-showed significantly increased neutrophil percentage and NLR but significantly lower lymphocyte-, eosinophil-, and basophil-related parameters compared to low YKL-40 patients ( = 24). These results reveal multidimensional, YKL-40-associated changes in leukocyte profile of patients with advanced COPD during acute exacerbations, with potential implications for personalized treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532402PMC
http://dx.doi.org/10.3390/jcm12186106DOI Listing

Publication Analysis

Top Keywords

serum ykl-40
12
acute exacerbations
12
percentage absolute
12
ykl-40 levels
8
exacerbations advanced
8
advanced copd
8
severe copd
8
copd gold
8
gold stage
8
median age
8

Similar Publications

Chitinase-3-like Protein 1 Reduces the Stability of Atherosclerotic Plaque via Impairing Macrophagic Efferocytosis.

J Cardiovasc Transl Res

January 2025

Department of Vascular and Endovascular Surgery, Changzheng Hospital, Affiliated to the Naval Medical University, Shanghai, 200003, China.

CHI3L1 is strongly associated with atherosclerosis, but its role in macrophages remains unknown. In this study, we observed a significant up-regulation of CHI3L1 in both carotid plaques and serum of symptomatic patients, and demonstrated that CHI3L1 impairs the efferocytosis of macrophages by down-regulating crucial efferocytic mediator MFGE8 through inhibiting ATF2, which binds directly to the enhancer of MFGE8. In human plaques, we observed a negative correlation between CHI3L1 expression and both ATF2 and MFGE8 levels, further proved their involvement in plaque destabilization.

View Article and Find Full Text PDF

Evaluation of Serum YKL-40 in Canine Multicentric Lymphoma: Clinical and Diagnostic Implications.

Animals (Basel)

November 2024

Department of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, No. 1 Sec. 4, Roosevelt Rd., Taipei City 106319, Taiwan.

YKL-40, a secretory glycoprotein, is known as a prognostic biomarker in human cancers, but its role in canine multicentric lymphoma is not well understood. This study aimed to investigate serum YKL-40 levels in thirty dogs with multicentric lymphoma to determine their prognostic value, association with patient characteristics, and potential to predict chemotherapy response. Serum samples were collected before, during, and after chemotherapy, and YKL-40 level was measured using ELISA.

View Article and Find Full Text PDF

Accurate ante-mortem diagnosis of non-infectious meningoencephalomyelitis (NIME) in dogs is challenging due to the similarity of clinical presentations, imaging findings, and cerebrospinal fluid (CSF) analysis results with other diseases. This study aimed to apply state-of-the-art quantitative proteomic technology to identify novel biomarkers for NIME. Serum and CSF samples from 11 dogs were included, with the control group consisting of patients presenting with intervertebral disc disease (IVDD, n = 6) and the study group consisting of dogs suffering from NIME (n = 5).

View Article and Find Full Text PDF

Background: Chitinase 3-like-1 (CHI3L1), also known as YKL-40, is a potential biomarker for neuroinflammatory conditions. It is upregulated in Alzheimer's disease, multiple sclerosis, and traumatic brain injury. However, its involvement in pediatric tick-borne encephalitis (TBE) has not been addressed yet.

View Article and Find Full Text PDF

Background/objectives: Increased systemic concentrations of YKL-40 are seen in various inflammatory conditions. We explored the relationship between the serum YKL-40 concentrations and subsequent disease severity in patients with acute pancreatitis (AP).

Methods: Consecutive adults with AP were prospectively enrolled, and classified as having mild, moderate or severe disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!